Clinical trials: Cancer - Ovarian
Ovarian Neoplasms
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
This is an international, randomized phase II trial. The aim is to assess the efficacy and the safety of BI 6727 Versus investigator's best choice single agent cytotoxic in recurrent third and fourth lines platinum…
- Trial name
- NCT01121406
- Testing
- Paclitaxel, Gemcitabine, Topotecan
- Where
- 31 sites in Belgium, France and 3 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01716715
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 173 sites in United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer, Ovarian Cancer
Assessing the Time Demands of Cancer
A total of 80 individuals receiving treatment for metastatic breast or advanced stage ovarian cancer will be asked to complete a baseline survey and install the mobile app on their smartphone; carry the smartphone for 28…
- Trial name
- NCT05708703
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer.
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT00278343
- Testing
- cediranib maleate, laboratory biomarker analysis
- Where
- 28 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
This research is being done to test the safety of the combination of the study drugs fostamatinib and paclitaxel. This study tests different doses of the drugs to see which doses are safest in people with ovarian cancer when…
- Trial name
- NCT03246074
- Testing
- Fostamatinib 100 mg bid and Paclitaxel, Fostamatinib 150 mg bid and Paclitaxel, Fostamatinib 200 mg bid and Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ovarian Carcinoma
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
This randomized pilot early phase I trial studies how well denosumab works in BRCA1/2 mutations carriers scheduled for risk-reducing salpingo-oophorectomy.
- Trial name
- NCT03382574
- Testing
- Denosumab, Salpingo-Oophorectomy
- Where
- 6 sites in United States, Israel
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment
- Trial name
- NCT01611558
- Testing
- Ipilimumab
- Where
- 17 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Cancer, Fallopian Tube Neoplasms
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")
Participants with ovarian cancer usually get the drugs carboplatin and paclitaxel as initial treatment. In many participants the tumor will shrink, or even disappear, after treatment with these drugs.
- Conditions
- Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasm
- Trial name
- NCT00391118
- Testing
- enzastaurin, carboplatin, paclitaxel
- Where
- 15 sites in Belgium, Germany and 3 more
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients with ovarian epithelial or…
- Trial name
- NCT00091273
- Testing
- incomplete Freund's adjuvant, ovarian cancer peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Virginia
Polycystic Ovary Syndrome
The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome
Adults with abdominal obesity are at high risk for cardiovascular disease and also exhibit diminished growth hormone (GH) secretion; the latter further contributes to the development of visceral adiposity, impaired fibrinolysis…
- Trial name
- NCT02122380
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt University
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Colorectal Cancer, Ovarian Cancer
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
This is a two-part Phase 1/2 dose escalation and dose expansion study of an Adenovirus Vector (Ad5/3-D24-GMCSF), Expressing GM-CSF (GM-CSF-encoding adenovirus), ONCOS-102, in combination with anti-programmed death ligand-1…
- Conditions
- Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
- Trial name
- NCT02963831
- Testing
- ONCOS-102, Durvalumab, Cyclophosphamide
- Where
- 6 sites in United States
- Volunteers
- 67 people
- Sponsor
- Ludwig Institute for Cancer Research
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
This phase II trial is studying how well giving cisplatin together with flavopiridol works in treating patients with advanced ovarian epithelial cancer or primary peritoneal cancer.
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer
- Trial name
- NCT00083122
- Testing
- cisplatin, alvocidib, cisplatin/flavopiridol
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Polycystic Ovary Syndrome, Cardiovascular Disease
LIPT - Liraglutide in Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.
- Trial name
- LIPT (NCT02073929)
- Testing
- Liraglutide for 26 weeks
- Where
- 3 sites in Denmark
- Volunteers
- 72 people
- Sponsor
- Jens Faber
Ovarian Cancer, Peritoneal Cancer
Abraxane/Bevacizumab
The protocol will study the effect of the combination of two drugs-Abraxane and Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Trial name
- NCT01821859
- Testing
- Abraxane, Bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Ovarian Cancer, Ovarian Neoplasms
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pegylated liposomal doxorubicin (PLD), a type of chemotherapy, is a standard treatment option for patients with platinum-resistant ovarian cancer.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT05261490
- Testing
- maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD)
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Gastrointestinal Neoplasms, Ovarian Neoplasms
Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
The purposes of this study are: 1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy ) or WART(Whole Abdominal Radiation Therapy) given in combination with standard fixed dose-rate…
- Trial name
- GCC0319 (NCT00390182)
- Testing
- Gemcitabine
- Where
- 2 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- University of Maryland, Baltimore
Neoplasms
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02122146
- Testing
- PF-06664178
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Endometrial Cancer, Uterine Cancer
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma
- Conditions
- Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma
- Trial name
- P204 (NCT03395080)
- Testing
- Paclitaxel, 300mg DKN-01, 600mg DKN-01
- Where
- 17 sites in United States
- Volunteers
- 111 people
- Sponsor
- Leap Therapeutics, Inc.
Recurrent Ovarian Cancer, Fallopian Tube Carcinoma
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
- Conditions
- Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01381861
- Testing
- Carotuximab (TRC105)
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Tracon Pharmaceuticals Inc.